TrialNeuro-oncology2016

AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.

Alba A Brandes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.